Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Triosephosphate isomerase 1 (TPI1) is a highly conserved, homodimeric enzyme essential for glycolysis, catalyzing the reversible interconversion of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate without cofactors. It is structurally characterized by the TIM barrel fold and displays “catalytic perfection,” limited only by substrate diffusion rates. TPI1 is expressed in almost all eukaryotes and many prokaryotes, with additional non-canonical functions being investigated, such as nuclear signaling relationships and contributions to cancer biology. Deficiency or malfunction due to genetic mutations causes severe, early-onset anemia, neuromuscular and metabolic dysfunction, reflecting its indispensability for cellular energy production. While not a current direct drug target, the enzyme’s central role in metabolism and implications for disease make it an area of active research.
Chemical inhibitors bind at the active site, competing with substrate or mimicking transition states, thus blocking isomerase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Triosephosphate isomerase 1 (TPI1).